Loyola University Chicago
His scientific interests lie mostly in Virology, Hepatitis C virus, Immunology, Hepacivirus and Virus. Harel Dahari is involved in the study of Virology that focuses on Viral replication in particular. He has included themes like Daclatasvir and NS5A in his Viral replication study.
His Hepatitis C virus research integrates issues from Interferon and Viral load. His Viral load research incorporates elements of Internal medicine, Danoprevir, Hepatitis c viral and Polymerase chain reaction. His Hepacivirus study incorporates themes from Telaprevir and Drug resistance.
Harel Dahari spends much of his time researching Virology, Hepatitis C virus, Internal medicine, Virus and Hepatitis C. His Viral replication, Hepatitis B virus, Interferon and HBsAg study in the realm of Virology connects with subjects such as Kinetics. Hepatitis C virus is frequently linked to Viral load in his study.
He combines subjects such as Gastroenterology and Sofosbuvir with his study of Internal medicine. His study in the fields of Titer under the domain of Virus overlaps with other disciplines such as Lonafarnib. His research in Hepatitis C intersects with topics in Liver disease, Hcv elimination and Incidence.
The scientist’s investigation covers issues in Virology, Hepatitis C, Hepatitis C virus, Internal medicine and Hepatitis B virus. His work on HBsAg, Hepatitis D virus and Hepatitis B as part of general Virology research is frequently linked to Chemistry and Mode of action, thereby connecting diverse disciplines of science. His research integrates issues of Hcv elimination, Incidence and Virological response in his study of Hepatitis C.
Hepatitis C virus is a subfield of Virus that he tackles. The Internal medicine study combines topics in areas such as Gastroenterology, Ribavirin, Sofosbuvir and Viral load. His study in Hepatitis B virus is interdisciplinary in nature, drawing from both Acquired immune system, Interferon, Pegylated interferon and Intracellular.
Harel Dahari mostly deals with Internal medicine, Hepatitis C, Hepatitis C virus, Gastroenterology and Viral load. The concepts of his Hepatitis C study are interwoven with issues in Hcv transmission, Incidence and Environmental health. His Hepatitis C virus research includes elements of Treatment duration and Vaccination.
His Gastroenterology study combines topics in areas such as Solid organ transplantation, Response to therapy, Baseline level, Virological response and Antihistamine. His research in Viral load tackles topics such as Liver disease which are related to areas like Organ transplantation, Transplantation, Hepatitis B virus and Cirrhosis. His Antiviral therapy study is concerned with Virology in general.
This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.
Hepatitis C Viral Dynamics in Vivo and the Antiviral Efficacy of Interferon-α Therapy
Avidan U. Neumann;Nancy P. Lam;Harel Dahari;David R. Gretch.
Rapid Emergence of Protease Inhibitor Resistance in Hepatitis C Virus
Libin Rong;Harel Dahari;Ruy M. Ribeiro;Alan S. Perelson.
Science Translational Medicine (2010)
Modeling shows that the NS5A inhibitor daclatasvir has two modes of action and yields a shorter estimate of the hepatitis C virus half-life
Jeremie Guedj;Harel Dahari;Harel Dahari;Harel Dahari;Libin Rong;Natasha D. Sansone;Natasha D. Sansone.
Proceedings of the National Academy of Sciences of the United States of America (2013)
Antiviral action of ribavirin in chronic hepatitis C.
Jean Michel Pawlotsky;Harel Dahari;Avidan U. Neumann;Christophe Hezode.
Clinical utility of total HCV core antigen quantification: a new indirect marker of HCV replication.
Magali Bouvier-Alias;Keyur Patel;Harel Dahari;Stéphanie Beaucourt.
Differences in viral dynamics between genotypes 1 and 2 of hepatitis C virus.
Avidan U. Neumann;Avidan U. Neumann;Nancy P. Lam;Harel Dahari;Harel Dahari;Marie Davidian.
The Journal of Infectious Diseases (2000)
Oral prenylation inhibition with lonafarnib in chronic hepatitis D infection: a proof-of-concept randomised, double-blind, placebo-controlled phase 2A trial.
Christopher Koh;Laetitia Canini;Laetitia Canini;Harel Dahari;Harel Dahari;Xiongce Zhao.
Lancet Infectious Diseases (2015)
Modeling hepatitis C virus dynamics: liver regeneration and critical drug efficacy.
Harel Dahari;Arthur Lo;Ruy M. Ribeiro;Alan S. Perelson.
Journal of Theoretical Biology (2007)
Hepatitis C virus kinetics and host responses associated with disease and outcome of infection in chimpanzees
Marian E. Major;Harel Dahari;Kathleen Mihalik;Montserrat Puig.
Triphasic decline of hepatitis C virus RNA during antiviral therapy
Harel Dahari;Ruy M. Ribeiro;Alan S. Perelson.
If you think any of the details on this page are incorrect, let us know.
We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below: